In most cases, Fidelis Care does not cover Wegovy for weight loss. The insurer’s Medicaid managed care, Essential Plan, Child Health Plus, and Ambetter Marketplace plans each either exclude weight-loss drugs outright or leave Wegovy off the formulary, and Fidelis Care’s own pharmacy guidance notes that “treatment of obesity is an excluded benefit for many plans.”1Fidelis Care. GLP-1 Agonist Pharmacy Information Medicare members enrolled in Wellcare by Fidelis Care have one separate route: a federal demonstration program that pays for Wegovy at a $50 monthly copay beginning July 1, 2026.
What Each Fidelis Care Plan Covers
Medicaid Managed Care and HealthierLife (HARP)
If you have Fidelis Care Medicaid or the HealthierLife HARP plan, your pharmacy benefits run through NYRx, New York’s state Medicaid pharmacy program, not through Fidelis Care directly.2Fidelis Care. Member Pharmacy Information NYRx states plainly that “weight loss is not and never has been a Medicaid-covered indication” and that “GLP-1 agonists, including but not limited to Ozempic, Wegovy, and Mounjaro are excluded from coverage for weight loss indications.”3NYRx. Drug Class Coverage Overview
The exclusion is written into New York regulation. 18 NYCRR § 505.3(g)(3) says “no payment will be made for any drug which has weight reduction as its sole clinical use.”4Cornell Law Institute. 18 NYCRR § 505.3 – Drugs Federal Medicaid law permits states to carve out weight-loss drugs, and New York has. As of January 2026, only 13 state Medicaid programs cover GLP-1s for obesity under fee-for-service, and New York is not one of them.5KFF. Medicaid Coverage of and Spending on GLP-1s
A bill introduced in the New York State Assembly, A9360, would require Medicaid to cover FDA-approved GLP-1s for obesity and related conditions. As of early 2026 it is sitting in the Assembly Health Committee and has not advanced.6New York State Senate. A9360
Essential Plan
The 2026 Essential Plan formulary, updated in April 2026, does not list Wegovy, Ozempic, or any GLP-1 approved for weight loss. The anti-obesity section includes only ADHD and narcolepsy drugs, and medications not on the formulary are not covered unless a formulary exception is granted.7Fidelis Care. Essential Plan 2026 Formulary
Ambetter from Fidelis Care (Marketplace QHP)
The Ambetter QHP formulary, updated in June 2026, does not include Wegovy. It does cover older weight-loss options: Contrave on Tier 3 with prior authorization and quantity limits, and phentermine and phentermine-topiramate on Tier 1 with prior authorization.8Fidelis Care. QHP 2026 Formulary Pharmacy benefits for Ambetter are managed by Express Scripts.9Fidelis Care. Ambetter Resources A Marketplace member who wants Wegovy would generally need to show that the covered alternatives were tried and failed, or are medically inappropriate.
Child Health Plus
The 2026 Child Health Plus formulary, updated in June 2026, lists no anti-obesity medications beyond ADHD-related stimulants. Wegovy is not covered.10Fidelis Care. Child Health Plus 2026 Formulary
Wellcare by Fidelis Care (Medicare)
Medicare Part D has long been barred from covering drugs prescribed solely for weight loss. Wellcare by Fidelis Care says “weight-loss-only drugs remain excluded” under Part D, and GLP-1 coverage is limited to FDA-approved indications such as type 2 diabetes and cardiovascular risk reduction.11Wellcare. Does Medicare Cover Weight Loss Drugs Starting July 2026, Medicare members have a separate federal pathway described in the next section.
The Medicare GLP-1 Bridge: A Separate Path for Wellcare Members
CMS launched the Medicare GLP-1 Bridge, a temporary nationwide demonstration, effective July 1, 2026. It covers Wegovy (injection and tablet), Zepbound, and Foundayo specifically for weight loss, outside the standard Part D benefit, with a flat $50 monthly copay.12Medicare.gov. Weight Loss Drugs
Importantly, Fidelis Care does not have to opt in. CMS runs the program through a central processor (Humana), which handles prior authorization, claims, and pharmacy payments directly. Prescribers submit prior authorization to the central processor rather than to the Part D plan, and pharmacies bill using a CMS-designated identifier. Any Medicare beneficiary with a qualifying Part D or Medicare Advantage drug plan can use the Bridge regardless of their insurer.13CMS. Medicare GLP-1 Bridge
Eligibility requires being 18 or older with Medicare drug coverage and meeting one of three BMI tiers:
- BMI of 35 or higher
- BMI of 30 to 34.99 with at least one qualifying condition such as heart failure, uncontrolled hypertension, chronic kidney disease, or prediabetes
- BMI of 27 to 29.99 with prediabetes, a history of heart attack or stroke, or symptomatic peripheral artery disease
The prescriber must also certify that you are participating in a lifestyle program involving diet and exercise.12Medicare.gov. Weight Loss Drugs If you already get Wegovy covered through your Part D plan for another indication, such as cardiovascular risk reduction, you cannot use the Bridge and must stay with your standard benefit.13CMS. Medicare GLP-1 Bridge
Approved prior authorizations under the Bridge remain valid through December 31, 2027.12Medicare.gov. Weight Loss Drugs One caveat: the $50 copay does not count toward Part D deductibles or out-of-pocket limits, and cost-assistance programs like Extra Help do not apply to it.14Medicare Rights Center. GLP-1 Weight Loss Drug Demonstration Begins July 2026
What a Denial Looks Like
A 2022 external appeal reviewed by the New York Department of Financial Services shows how these rules work in practice. A Fidelis Care Medicaid member in his 40s, with a BMI between 35 and 35.9, obesity, fatty liver disease, and abnormal glucose levels, asked for Wegovy. Fidelis Care denied the request as not medically necessary, and an independent reviewer upheld the denial because the member’s records did not show he had tried and failed Ozempic, Trulicity, and Victoza. The reviewer noted that “Ozempic is the same medication packaged in a different dosage” and found no evidence that Wegovy would be safer or more effective than the covered alternatives.15NY DFS. External Appeal Decision 202212-156978
Two things are worth taking from this. The weight-loss indication itself is excluded for Medicaid, so appeals end up turning on narrower medical-necessity grounds tied to other conditions. And even when a member has conditions that might justify a GLP-1, step therapy requirements usually mean documenting failure of cheaper preferred drugs first.
Requesting a Formulary Exception or Appealing a Denial
If Wegovy is not on your Fidelis Care formulary, you can ask for a formulary exception. The process depends on your plan.
For Wellcare by Fidelis Care Medicare plans, your prescriber completes a Medication Request Form explaining the medical reasons the exception is necessary. The form can be submitted by phone at 1-800-247-1447, by fax to 1-866-226-1093, or by mail to the Medicare Pharmacy Prior Authorization Department in Tampa, Florida.16Fidelis Care. Coverage Determination Request Form Standard requests must be decided within 72 hours; expedited requests, when the prescriber confirms that waiting could seriously harm the member, must be decided within 24 hours.17CMS. Part D Coverage Determination and Exception Requests If the exception is denied, you can file a redetermination within 65 days of the denial notice, online, by fax to 1-866-388-1766, or by mail. A temporary supply may be available through the plan’s transition policy while you wait.18Fidelis Care. Prescription Drug Information
For the Essential Plan and Ambetter plans, members may also request exceptions for non-formulary drugs. The prescriber submits a Medication Request Form with medical justification, and the request is reviewed against clinical criteria such as documented failure of preferred agents or adverse reactions to alternatives.7Fidelis Care. Essential Plan 2026 Formulary
When coverage is available at all, Fidelis Care’s own guidance says it may ask for documentation to back up claims made during prior authorization, and a common reason for denial is failing to try a formulary alternative first.1Fidelis Care. GLP-1 Agonist Pharmacy Information
Paying for Wegovy Without Fidelis Care Coverage
If your Fidelis Care plan does not cover Wegovy and an exception is not available, Novo Nordisk offers direct options through its NovoCare platform. A savings card can bring the cost to as low as $25 per month for people with commercial insurance from another source, but anyone with government-funded coverage, including Medicaid, is explicitly ineligible for that offer.19NovoCare. Wegovy Savings Offer
For patients paying out of pocket, NovoCare Pharmacy prices Wegovy at $149 per month for the 1.5 mg and 4 mg doses (the 4 mg price rises to $199 per month after August 31, 2026), with an introductory price of $199 per month on the two lowest starter doses for new patients, climbing to $349 per month after the first two fills.20Wegovy. What to Pay for Wegovy You can call the Wegovy Navigation Line at 1-833-4-WEGOVY for help identifying coverage options, or text “SAVE” to 83757 to enroll in savings programs.21Wegovy. Save on Wegovy